Published in Women's Health Weekly, November 20th, 2003
At the time of interim analysis, eight patients being treated at Telcyta (500 mg/m2) and carboplatin (AUC 5 or 6) are evaluable. All patients have platinum refractory or resistant disease. Five of the eight evaluable patients (63%) have objective tumor responses by the RECIST criteria, including one complete response.
The overall disease stabilization rate is 88%. Telcyta in combination with carboplatin has been well-tolerated in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly